Food and Wine Food and Wine

Seattle biotech startup Tune Therapeutics lands $175M to support clinical research


Published on 2025-01-12 20:42:18 - MSN
  Print publication without navigation

  • Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years.

Tune Therapeutics, a Seattle-based biotech startup, has successfully raised $175 million in a Series B funding round to advance its clinical research. The company focuses on developing treatments for genetic diseases using its proprietary genome editing technology, known as TEMPO (Targeted Epigenetic Modulation and Programming). This technology allows for precise, programmable control over gene expression without altering the underlying DNA sequence, offering potential treatments for conditions like chronic pain, autoimmune diseases, and various genetic disorders. The funding will support the expansion of Tune's research and development efforts, including the progression of its lead programs into clinical trials. The investment round was led by prominent venture capital firms, highlighting the growing interest and confidence in Tune's innovative approach to gene therapy.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/science/biology/seattle-biotech-startup-tune-therapeutics-lands-175m-to-support-clinical-research/ar-BB1rkHtA ]